Direkt zum Inhalt
Merck

AROS has a context-dependent effect on SIRT1.

FEBS letters (2014-04-01)
Tarja Kokkola, Tiina Suuronen, Ferdinand Molnár, Juha Määttä, Antero Salminen, Elina M Jarho, Maija Lahtela-Kakkonen
ZUSAMMENFASSUNG

The modulation of protein deacetylase SIRT1 has a vast therapeutic potential in treatment of several aging-associated diseases. Active regulator of SIRT1 (AROS) is a small endogenous protein which was originally reported to activate SIRT1 through a direct interaction in cancer cells. We show that the interaction between the two proteins is weak and does not alter the activity of SIRT1 in non-cancerous human cells. The results of different in vitro SIRT1 activity assays disclosed AROS as an inhibitor of SIRT1. The functional relationship between AROS and SIRT1 proved to be dependent on the biological context and experimental setting.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Monoklonaler Anti-α-Tubulin-Antikörper in Maus hergestellte Antikörper, ascites fluid, clone B-5-1-2
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, ≥95% (HPLC)
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, ≥99%
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, suitable for cell culture, ≥96.5% (HPLC), ≥96.5% (spectrophotometric assay), from yeast
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, Grade AA-1
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid, pkg of 10 mg (per vial)
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, ≥98%, BioUltra, from yeast
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid, pkg of 50 mg (per vial)
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid Hydrat, purified by column chromatography, ≥99%
Sigma-Aldrich
β-Nicotinamidadenin-Dinucleotid, pkg of 20 mg (per vial)
Sigma-Aldrich
Anti-RPS19BP1 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution